{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:27:47Z","timestamp":1781713667671,"version":"3.54.5"},"reference-count":46,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA290062"],"award-info":[{"award-number":["K08CA290062"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA295495"],"award-info":[{"award-number":["P50CA295495"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention & Research Institute of Texas","doi-asserted-by":"crossref","award":["RP200549"],"award-info":[{"award-number":["RP200549"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability\/progression after atezolizumab with and without bevacizumab across several histologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc individual-level analysis of 2980 patients across eight randomized trials of atezolizumab in non-small cell lung cancer, urothelial carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analyses of the temporal characteristics of atypical responses revealed two distinct patterns including primary and secondary pseudo-stability\/progression. Primary pseudo-stability\/progression is characterized by initial disease progression and subsequent regression, which occurs in 7.7%\u201312.5% of patients according to cancer type. In contrast, secondary progression is characterized by initial disease control with subsequent radiographic progression followed by tumor regression, and this occurs in 4.4%\u201310.8% of patients according to cancer type. Compared with patients matched by the same initial radiographic response, primary and secondary pseudo-stability\/progression could be associated with similar or inferior overall survival outcomes depending on the cancer type and classification of the initial tumor response. Exploratory analyses indicate that clinical factors are not predictive of atypical responses, but pseudo-stability\/progression could be associated with distinct genomic alterations including\n                      <jats:italic>TSC1\/2<\/jats:italic>\n                      in RCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Primary and secondary pseudo-stability\/progression occur in a non-trivial proportion of patients across cancer types. Outcomes after pseudo-stability\/progression are dependent on cancer type and initial response. Uncovering the clinical and molecular features of pseudo-stability\/progression subtypes may guide treatment decisions and identify patients who may benefit from continued immunotherapy despite radiographic progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013727","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:42Z","timestamp":1768590942000},"page":"e013727","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01903993","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02031458","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02008227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02108652","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02302807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01984242","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02420821","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03434379","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Saiabhiroop","family":"Govindu","sequence":"first","affiliation":[{"name":"Divison of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Gowda","sequence":"additional","affiliation":[{"name":"Divison of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maishara","family":"Muquith","sequence":"additional","affiliation":[{"name":"Divison of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-302X","authenticated-orcid":false,"given":"David","family":"Hsiehchen","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011611153798000_14.1.e013727.1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026011611153798000_14.1.e013727.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026011611153798000_14.1.e013727.3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0586"},{"key":"2026011611153798000_14.1.e013727.4","first-page":"1409","article-title":"The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review","volume":"11","author":"Moujaess","year":"2019","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026011611153798000_14.1.e013727.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011"},{"key":"2026011611153798000_14.1.e013727.6","first-page":"1","article-title":"Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026011611153798000_14.1.e013727.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"2026011611153798000_14.1.e013727.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0642-y"},{"key":"2026011611153798000_14.1.e013727.9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of Response and Progression to Immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026011611153798000_14.1.e013727.10","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0144"},{"key":"2026011611153798000_14.1.e013727.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026011611153798000_14.1.e013727.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1644"},{"key":"2026011611153798000_14.1.e013727.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"2026011611153798000_14.1.e013727.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.017"},{"key":"2026011611153798000_14.1.e013727.15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000146","article-title":"Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis","volume":"8","author":"Mulkey","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026011611153798000_14.1.e013727.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004849","article-title":"iRECIST and atypical patterns of response to immuno-oncology drugs","volume":"10","author":"Ramon-Patino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011611153798000_14.1.e013727.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026011611153798000_14.1.e013727.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2026011611153798000_14.1.e013727.19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/2767-9764.CRC-23-0025","article-title":"Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma","volume":"3","author":"Lim","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026011611153798000_14.1.e013727.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2027"},{"key":"2026011611153798000_14.1.e013727.21","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026011611153798000_14.1.e013727.22","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/cncr.32190","article-title":"Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial","volume":"125","author":"Haddad","year":"2019","journal-title":"Cancer"},{"key":"2026011611153798000_14.1.e013727.23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","article-title":"Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis","volume":"19","author":"Beaver","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026011611153798000_14.1.e013727.24","first-page":"235","article-title":"Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer","volume":"12","author":"Reinhorn","year":"2020","journal-title":"Immunotherapy (Los Angel)"},{"key":"2026011611153798000_14.1.e013727.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-12315-5","article-title":"Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"2026011611153798000_14.1.e013727.26","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0425-8","article-title":"Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab","volume":"6","author":"Zahoor","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026011611153798000_14.1.e013727.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026011611153798000_14.1.e013727.28","doi-asserted-by":"crossref","unstructured":"Sun Q , Hong Z , Zhang C , et al . Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Sig Transduct Target Ther 2023;8. doi:10.1038\/s41392-023-01522-4","DOI":"10.1038\/s41392-023-01522-4"},{"key":"2026011611153798000_14.1.e013727.29","doi-asserted-by":"crossref","first-page":"968517","DOI":"10.3389\/fonc.2022.968517","article-title":"Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"2026011611153798000_14.1.e013727.30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-24-3485","article-title":"Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026011611153798000_14.1.e013727.31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0b013e318204a3af","article-title":"The paradoxical effect of bevacizumab in the therapy of malignant gliomas","volume":"76","author":"Thompson","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2026011611153798000_14.1.e013727.32","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.jtho.2018.05.008","article-title":"CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC","volume":"13","author":"Rocha","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2026011611153798000_14.1.e013727.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29541-9","article-title":"STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming","volume":"13","author":"Chu","year":"2022","journal-title":"Nat Commun"},{"key":"2026011611153798000_14.1.e013727.34","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120540119","article-title":"Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1","volume":"119","author":"Oreskovic","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026011611153798000_14.1.e013727.35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41388-024-03221-y","article-title":"Emerging roles of cohesin-STAG2 in cancer","volume":"44","author":"Scott","year":"2025","journal-title":"Oncogene"},{"key":"2026011611153798000_14.1.e013727.36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03782-z","article-title":"STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection","volume":"9","author":"Ding","year":"2018","journal-title":"Nat Commun"},{"key":"2026011611153798000_14.1.e013727.37","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20080281"},{"key":"2026011611153798000_14.1.e013727.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2631"},{"key":"2026011611153798000_14.1.e013727.39","doi-asserted-by":"crossref","unstructured":"Lai M , Zou W , Han Z , et al . Tsc1 regulates tight junction independent of mTORC1. Proc Natl Acad Sci USA 2021;118. doi:10.1073\/pnas.2020891118","DOI":"10.1073\/pnas.2020891118"},{"key":"2026011611153798000_14.1.e013727.40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201796700"},{"key":"2026011611153798000_14.1.e013727.41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.tibs.2018.09.018","article-title":"The mTOR Independent Function of Tsc1 and FNIPs","volume":"43","author":"Sager","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"2026011611153798000_14.1.e013727.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00187-9"},{"key":"2026011611153798000_14.1.e013727.43","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.67"},{"key":"2026011611153798000_14.1.e013727.44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"key":"2026011611153798000_14.1.e013727.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.011"},{"key":"2026011611153798000_14.1.e013727.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0134-3"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:51Z","timestamp":1768590951000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013727"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013727","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}